Corvus Pharmaceuticals CRVS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$13.69M-11.1% | -$12.32M-21.3% | -$10.16M-27.0% | -$8M-153% | $15.19M+225% | ||
| $29K+11.5% | $26K-7.1% | $28K-3.4% | $29K+31.8% | $22K+10.0% | ||
| $2.65M+68.4% | $1.57M+26.0% | $1.25M-0.6% | $1.26M+0.4% | $1.25M+53.9% | ||
| —— | —— | —— | —— | —— | ||
| $2.21M— | —— | -$1.16M-164% | $1.83M+244% | -$1.27M-280% | ||
| $499K-34.8% | $765K+8.1% | $708K-38.0% | $1.14M+682% | $146K+130% | ||
| -$88K0.0% | -$88K-3.5% | -$85K-2.4% | -$83K-1.2% | -$82K-109% | ||
| -$599K+15.3% | -$707K-119% | -$323K+17.0% | -$389K+27.8% | -$539K+75.2% | ||
| -$103K-39.2% | -$74K-2.8% | -$72K-2.9% | -$70K-326% | $31K— | ||
| $865K+28,733% | $3K-98.7% | $226K+7,633% | -$3K0.0% | -$3K-101% | ||
| -$10.37M-12.9% | -$9.19M+3.9% | -$9.57M-65.6% | -$5.78M+30.1% | -$8.26M+2.4% | ||
| $91K+264% | $25K— | $0-100% | $113K+214% | $36K— | ||
| $161.74M+1,105% | $13.42M-56.9% | $31.15M-21.1% | $39.48M+412% | $7.71M-62.1% | ||
| $16.98M-30.2% | $24.32M-14.7% | $28.53M+47.9% | $19.29M+60.9% | $11.99M-16.0% | ||
| —— | —— | —— | —— | —— | ||
| -$144.85M— | —— | -$2.62M+87.1% | -$20.3M-578% | $4.24M+170% | ||
| $189.41M+946,935% | $20K-94.4% | $360K+1,340% | $25K-91.0% | $279K-93.2% | ||
| $190.75M+953,630% | $20K-94.4% | $360K-99.0% | $35.77M+12,721% | $279K-98.5% | ||
| $35.53M— | —— | -$11.82M-222% | $9.69M+359% | -$3.74M— | ||
| $17K-93.5% | $261K-43.1% | $459K+37.4% | $334K+14.8% | $291K+20.2% | ||
| -$599K+15.3% | -$707K-119% | -$323K+17.0% | -$389K+27.8% | -$539K+75.2% | ||
| $499K-34.8% | $765K+8.1% | $708K-38.0% | $1.14M+682% | $146K+130% | ||
| -$103K-39.2% | -$74K-2.8% | -$72K-2.9% | -$70K-326% | $31K— | ||
| $865K+28,733% | $3K-98.7% | $226K+7,633% | -$3K0.0% | -$3K-101% | ||
| $1.76M— | —— | -$64K— | —— | -$1.17M-200% | ||
| $16.98M-30.2% | $24.32M-14.7% | $28.53M+47.9% | $19.29M+60.9% | $11.99M-16.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$2.01M+92.0% | -$25.13M-1,171% | ||
| -$103K-39.2% | -$74K-2.8% | -$72K-2.9% | -$70K-326% | $31K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $442.25K0.0% | $442.25K0.0% | $442.25K0.0% | $442.25K-86.8% | ||
| $553K— | —— | —— | —— | —— | ||
| -$10.47M-13.6% | -$9.22M+3.7% | -$9.57M-62.4% | -$5.89M+29.0% | -$8.3M— | ||
| -$10.47M-13.6% | -$9.22M+3.7% | -$9.57M-62.4% | -$5.89M+29.0% | -$8.3M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Corvus Pharmaceuticals generate?
- Corvus Pharmaceuticals (CRVS) generated -$34.9M in operating cash flow over the trailing twelve months.
- What is Corvus Pharmaceuticals's free cash flow?
- After $229.0K of capital expenditures, Corvus Pharmaceuticals's free cash flow was -$35.1M over the trailing twelve months, down 45.7% year over year.
- Where does Corvus Pharmaceuticals's cash flow data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.